China Universal Asset Management Co. Ltd. Acquires 909 Shares of United Therapeutics Co. (NASDAQ:UTHR)

China Universal Asset Management Co. Ltd. grew its stake in United Therapeutics Co. (NASDAQ:UTHR) by 10.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,466 shares of the biotechnology company’s stock after acquiring an additional 909 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in United Therapeutics were worth $3,340,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Creative Planning increased its position in shares of United Therapeutics by 20.1% during the 2nd quarter. Creative Planning now owns 3,613 shares of the biotechnology company’s stock worth $1,151,000 after purchasing an additional 605 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in United Therapeutics by 10.2% during the second quarter. B. Riley Wealth Advisors Inc. now owns 1,067 shares of the biotechnology company’s stock worth $340,000 after buying an additional 99 shares during the last quarter. Cetera Investment Advisers raised its position in United Therapeutics by 8.7% during the second quarter. Cetera Investment Advisers now owns 6,167 shares of the biotechnology company’s stock worth $1,964,000 after acquiring an additional 493 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in United Therapeutics in the second quarter valued at $3,471,000. Finally, SG Americas Securities LLC grew its position in shares of United Therapeutics by 66.1% in the 3rd quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company’s stock valued at $535,000 after acquiring an additional 594 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group raised their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. HC Wainwright boosted their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH raised their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, TD Cowen lifted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Trading Down 0.3 %

Shares of UTHR opened at $351.17 on Friday. The stock has a market capitalization of $15.68 billion, a PE ratio of 15.42, a P/E/G ratio of 0.95 and a beta of 0.57. The firm’s 50 day moving average is $365.03 and its 200-day moving average is $356.94. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.38 EPS. Equities research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $1,034,510.88. This represents a 85.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 133,838 shares of company stock worth $50,445,556. Company insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.